TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.

R B Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.